KPV 10mg

KPV is a tripeptide composed of the amino acids lysine (K), proline (P), and valine (V), corresponding to residues 11-13 of the C-terminal end of alpha-melanocyte-stimulating hormone (α-MSH). Its discovery as an independent active entity stemmed from research into the systemic anti-inflammatory effects of α-MSH and its fragments.

Molecular characteristics:

• Molecular weight: 342.4 Da
• Sequence: H-Lys-Pro-Val-OH
• Stability: high resistance to gastrointestinal enzymatic degradation
• Acceptable oral bioavailability, in addition to parenteral and topical routes

Unlike full α-MSH, KPV does not induce melanogenesis or systemic effects on appetite, making it especially attractive as a purely anti-inflammatory agent without pigmentary or metabolic side effects.

KPV exerts its action through multiple anti-inflammatory pathways:

• NF-κB Inhibition blocks nuclear translocation of the master transcription factor of inflammation, reducing the production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6).
• Macrophage modulation induce polarization towards the M2 (anti-inflammatory and reparative) phenotype and reduces the M1 phenotype.
• Action on intestinal epithelial cells: improves intestinal barrier integrity, reduces permeability, and promotes epithelial regeneration.
• Melanocortin receptor activation preferentially binds to MC1R with lower affinity than α-MSH, which reduces pigmentary effects.

• Inflammatory bowel disease Improvement of clinical markers in ulcerative colitis and Crohn's disease in preclinical models
• Psoriasis and dermatitis reduction of plaques and improvement of itching in topical presentations
• Asthma and COPD Bronchial hyperreactivity research
• Leaky Gut Syndrome Restoration of tight junction integrity
• Autoimmunity Th17 response modulation and Treg cell regulation
• Post-exercise recovery: Reduction of low-grade inflammation in athletes

Reconstitution Add 2 ml of bacteriostatic water to the 10 mg vial. Resulting concentration: 5,000 mcg/ml. Each U-100 unit delivers 50 mcg.

Typical layouts:

• Inflammatory bowel disease: 500 to 1000 mcg/day subcutaneous (oral if using capsule formulation), 4 to 8 week cycles
• Aesthetics and skin: 250 to 500 mcg/day, minimum 6 weeks to see changes
• Post-workout recovery: 250 mcg post-exercise on high-load days

The safety profile is remarkably benign given its endogenous nature. Local injection site reactions and mild nausea are the most common adverse events. Avoid use in immunocompromised patients without professional supervision.

• Full intestinal recovery: KPV + BPC-157 for mucosal-systemic synergy
• Chronic inflammation KPV + TB-500 for reducing inflammation and improving tissue angiogenesis
• Autoimmunity KPV + Selank for immune modulation + stress
• Aesthetics and skin: KPV + GHK-Cu for anti-inflammatory and regenerative synergy

1. Brzoska T, Luger TA, Maaser C, et al. α-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo. Endocr Rev. 2008;29(5):581-602.
2. Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331.
3. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178.